Sponsor content
37 result(s) found, displaying 1 to 10
- Australian Public Assessment Report (AusPAR)AusPAR: PadcevAusPAR for Padcev (Enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed receptor-1 or programmed death-ligand-1 inhibitor.
- Feb-2023Prescription medicine evaluationVEOZA Astellas Pharma Australia Pty LtdActive ingredient: fezolinetant.
- Prescription medicine decision summaryPadcevPadcev (enfortumab vedotin) is approved to treat adult patients with locally advanced or metastatic urothelial cancer.
- ARTGPADCEV enfortumab vedotin 20 mg powder for injection vial (355870)Australian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 20 mg powder for injection vial.
- ARTGPADCEV enfortumab vedotin 30 mg powder for injection vial (367410)Australian Register of Therapeutic Goods (ARTG) information for PADCEV enfortumab vedotin 30 mg powder for injection vial.
- Prescription medicine registrationPADCEV (Astellas Pharma Australia Pty Ltd)Active ingredients: enfortumab vedotin.
- Australian Public Assessment Report (AusPAR)AusPAR: Gilteritinib (as fumarate)New AusPAR for Xospata (gilteritinib as fumarate) for the treatment of relapsed or refractory acute myeloid leukaemia (AML)
- Prescription medicine registrationXOSPATA (Astellas Pharma Australia Pty Ltd)Active ingredients: gilteritinib fumarate.
- ARTGXOSPATA gilteritinib (as fumarate) 40 mg film-coated tablet blister pack (321060)Australian Register of Therapeutic Goods (ARTG) information for XOSPATA gilteritinib (as fumarate) 40 mg film-coated tablet blister pack.